{"title":"碳离子放射治疗的效果相当于肝细胞癌的手术切除。","authors":"Takeshi Hatanaka, Kei Shibuya, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Kazuya Kariyama, Ei Itobayashi, Kunihiko Tsuji, Toru Ishikawa, Hidenori Toyoda, Yuichi Koshiyama, Atsushi Naganuma, Yuhei Miyasaka, Yuki Kanayama, Kazunari Tanaka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Shinichiro Nakamura, Takashi Kumada, Tatsuya Ohno","doi":"10.1097/HC9.0000000000000801","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to compare the clinical outcomes of carbon-ion radiotherapy (CIRT) to those of surgical resection (SR) in patients with HCC.</p><p><strong>Methods: </strong>This retrospective study included 116 and 947 patients initially receiving CIRT and SR in Japanese institutions from September 2010 and June 2022. We used inverse probability of treatment weighting (IPTW) analysis to correct for imbalances in baseline patient characteristics between the 2 groups.</p><p><strong>Results: </strong>The median observation period was 3.3 years (IQR: 1.4-5.8) in the SR group and 2.8 years (IQR: 1.6-4.5) in the CIRT group (p=0.2). Before IPTW analysis, the median recurrence-free survival (RFS) was 2.3 years in the SR group and 2.2 years in the CIRT group, with no statistical significance (p=0.3). After IPTW analysis, the median RFS was 2.5 years in the SR group and 2.3 years in the CIRT group, which remained statistically nonsignificant (p=0.9). The median overall survival (OS) was not reached in the SR group, while it was 7.4 years in the CIRT group. The SR group demonstrated better survival compared to the CIRT group (p=0.02). In the IPTW cohort, the median OS was not reached in the SR group, while it remained 7.4 years in the CIRT group, showing no significant difference (p=0.4). Multivariate analyses showed that treatment choice (SR vs. CIRT) was not identified as a predictive factor for both RFS and OS.</p><p><strong>Conclusions: </strong>CIRT showed no statistically significant differences in RFS or OS compared with SR, suggesting its potential as a curative treatment option for early-stage HCC.</p>","PeriodicalId":12978,"journal":{"name":"Hepatology Communications","volume":"9 9","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401240/pdf/","citationCount":"0","resultStr":"{\"title\":\"Carbon-ion radiotherapy achieves outcomes equivalent to surgical resection for hepatocellular carcinoma.\",\"authors\":\"Takeshi Hatanaka, Kei Shibuya, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Kazuya Kariyama, Ei Itobayashi, Kunihiko Tsuji, Toru Ishikawa, Hidenori Toyoda, Yuichi Koshiyama, Atsushi Naganuma, Yuhei Miyasaka, Yuki Kanayama, Kazunari Tanaka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Shinichiro Nakamura, Takashi Kumada, Tatsuya Ohno\",\"doi\":\"10.1097/HC9.0000000000000801\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>This study aimed to compare the clinical outcomes of carbon-ion radiotherapy (CIRT) to those of surgical resection (SR) in patients with HCC.</p><p><strong>Methods: </strong>This retrospective study included 116 and 947 patients initially receiving CIRT and SR in Japanese institutions from September 2010 and June 2022. We used inverse probability of treatment weighting (IPTW) analysis to correct for imbalances in baseline patient characteristics between the 2 groups.</p><p><strong>Results: </strong>The median observation period was 3.3 years (IQR: 1.4-5.8) in the SR group and 2.8 years (IQR: 1.6-4.5) in the CIRT group (p=0.2). Before IPTW analysis, the median recurrence-free survival (RFS) was 2.3 years in the SR group and 2.2 years in the CIRT group, with no statistical significance (p=0.3). After IPTW analysis, the median RFS was 2.5 years in the SR group and 2.3 years in the CIRT group, which remained statistically nonsignificant (p=0.9). The median overall survival (OS) was not reached in the SR group, while it was 7.4 years in the CIRT group. The SR group demonstrated better survival compared to the CIRT group (p=0.02). In the IPTW cohort, the median OS was not reached in the SR group, while it remained 7.4 years in the CIRT group, showing no significant difference (p=0.4). Multivariate analyses showed that treatment choice (SR vs. CIRT) was not identified as a predictive factor for both RFS and OS.</p><p><strong>Conclusions: </strong>CIRT showed no statistically significant differences in RFS or OS compared with SR, suggesting its potential as a curative treatment option for early-stage HCC.</p>\",\"PeriodicalId\":12978,\"journal\":{\"name\":\"Hepatology Communications\",\"volume\":\"9 9\",\"pages\":\"\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401240/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatology Communications\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/HC9.0000000000000801\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Communications","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/HC9.0000000000000801","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Carbon-ion radiotherapy achieves outcomes equivalent to surgical resection for hepatocellular carcinoma.
Aim: This study aimed to compare the clinical outcomes of carbon-ion radiotherapy (CIRT) to those of surgical resection (SR) in patients with HCC.
Methods: This retrospective study included 116 and 947 patients initially receiving CIRT and SR in Japanese institutions from September 2010 and June 2022. We used inverse probability of treatment weighting (IPTW) analysis to correct for imbalances in baseline patient characteristics between the 2 groups.
Results: The median observation period was 3.3 years (IQR: 1.4-5.8) in the SR group and 2.8 years (IQR: 1.6-4.5) in the CIRT group (p=0.2). Before IPTW analysis, the median recurrence-free survival (RFS) was 2.3 years in the SR group and 2.2 years in the CIRT group, with no statistical significance (p=0.3). After IPTW analysis, the median RFS was 2.5 years in the SR group and 2.3 years in the CIRT group, which remained statistically nonsignificant (p=0.9). The median overall survival (OS) was not reached in the SR group, while it was 7.4 years in the CIRT group. The SR group demonstrated better survival compared to the CIRT group (p=0.02). In the IPTW cohort, the median OS was not reached in the SR group, while it remained 7.4 years in the CIRT group, showing no significant difference (p=0.4). Multivariate analyses showed that treatment choice (SR vs. CIRT) was not identified as a predictive factor for both RFS and OS.
Conclusions: CIRT showed no statistically significant differences in RFS or OS compared with SR, suggesting its potential as a curative treatment option for early-stage HCC.
期刊介绍：
Hepatology Communications is a peer-reviewed, online-only, open access journal for fast dissemination of high quality basic, translational, and clinical research in hepatology. Hepatology Communications maintains high standard and rigorous peer review. Because of its open access nature, authors retain the copyright to their works, all articles are immediately available and free to read and share, and it is fully compliant with funder and institutional mandates. The journal is committed to fast publication and author satisfaction.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
